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 Plant derivatives such as carotenoids and phytosterols enrich foods have been shown to reduce 
plasma Triglyceride (TG), low density lipoprotein cholesterol (LDL), and cholesterol 
concentrations. The aim of this systematic review and meta-analyses study was investigation 
the effects of saffron on lipid profiles, reported in Randomized Control Trials. We performed 
a systematic electronic search in PubMed/MEDLINE, Cochrane and SCOPUS to identify 
randomised controlled trials and screening of relevant articles references up to October 12th, 
2018. There were no language restrictions. We performed this systematic review and meta-
analysis according to the Preferred Items for Reporting of Systematic Reviews and Meta-
Analyses (PRISMA) guidelines. we identified and analyzed fourteen eligible studies in this 
meta-analysis. Our study found a significant reduction in cholesterol and triglycerides 
following saffron intervention (Weighted mean difference [WMD]: -6.36 mg/dl, 95% CI: -
10.58, -2.18) and (WMD: -5.37 mg/dl, 95% CI: -10.25, -0.48), respectively. There was no 
significant effect on Weight and LDL concentration. A meta regression analysis showed that 
Long-term saffron intervention can increase the HDL levels. In conclusions, our study findings 
indicate some benefits of saffron on cholesterol, HDL, and triglycerides compared to placebo. 
However, we recommend the conduct of adequately powered, high quality RCTs with short 
and long-term follow up, evaluating relevant clinical outcomes to allow for making definitive 
recommendations. 
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 Introduction  
The most common strategies for the prevention or reversal of obesity, and many associated 
blood lipid disorders, are dietary control or manipulation, and physical activity. However, in 
recent years the interest in the utility of conjunctive or alternative therapies has proliferated. 
Of contemporary interest are dietary phytochemicals, which are ostensibly considered 
therapeutic agents to counter obesity, and associated dyslipidemia (Baboota et al., 2013; 
Hasani-Ranjbar, Larijani, & Abdollahi, 2009). Such compounds utilize anti-obesity properties 
by regulating lipid absorption, modulating energy intake and expenditure, decreasing 
lipogenesis and increasing lipolysis, and differentiating the proliferation of pre-adipocytes 
(González-Castejón & Rodriguez-Casado, 2011). Saffron, Crocus sativus L., belongs to the 
Iridaceae family, and is a common plant widely cultivated in Iran, India and the Mediterranean. 
Moreover, a variety of biologically active ingredients have been isolated from saffron. It is 
accepted that crocin (monoglycosyl or diglycosyl esters of crocetin), crocetin (a natural 
carotenoid dicarboxylic acid precursor of crocin), picrocrocin (monoterpene glycoside 
precursor of safranal), and safranal (the major organoleptic principle of the stigmas) comprise 
the four major bioactive compounds of saffron and are responsible not only for its sensory 
profile but also for its health-promoting properties (Ochiai et al., 2007; Xiang, Qian, Zhou, Liu, 
& Li, 2006). In recent decades, saffron has been asserted to, purportedly, possess many 
therapeutic properties, with growing evidence that saffron has a conceivable anti-obesity, 
therapeutic effect (Mashmoul, Azlan, Khaza'ai, Yusof, & Noor, 2013). Saffron contains a rich 
source of carotenoids (crocin), glycoside (picrocrocin) and a volatile oil component (safranal) 
(Fernández, 2004; WINTERHALTER & STRAUBINGER, 2000). Crocin, one of the major 
bioactive constituents, and has a plethora of biological activities, including antigenotoxic and 
cytotoxic effects (Abdullaev, 2006; G Gutheil, Reed, Ray, Anant, & Dhar, 2012), antioxidant 
(Charles, 2013; Chen et al., 2008), antinociceptive and anti-inflammatory (Poma, Fontecchio, 
Carlucci, & Chichiricco, 2012), anti atherosclerotic (Kamalipour & Akhondzadeh, 2011), anti-
diabetic (Shirali, Zahra Bathaie, & Nakhjavani, 2013), hypotensive (Imenshahidi, 
Hosseinzadeh, & Javadpour, 2010), hypolipidaemic(Sheng, Qian, Zheng, & Xi, 2006), 
hypoglycemic (Kianbakht & Mozaffari, 2009; Mohajeri, Mousavi, & Doustar, 2009), 
antidepressant(Gout, Bourges, & Paineau Dubreuil, 2010; Sahraian, Jelodar, Javid, Mowla, & 
Ahmadzadeh, 2016) and satiety enhancing (Gout et al., 2010). There is a general consensus on 
the positive, supporting role of saffron, or its active constituents, in modulating serum total 
cholesterol (TC), total triglyceride (TG), low density lipoprotein cholesterol (LDL), and high-
density lipoprotein cholesterol (HDL) (Arasteh et al., 2010; Hoshyar et al., 2016; 
Samarghandian, Azimi Nezhad, & Samini, 2014; Shirali et al., 2013). In an in vitro study, 
crocetin decreased the levels of Reactive Oxygen Species, free radical-mediated lipid 
peroxidation, and increased radical scavenging activity (Xiang et al., 2006). Furthermore, 
saffron has been reported to possess anti-inflammatory properties (Ochiai et al., 2007). Saffron 
reportedly improves the lipid profile and increases glucose uptake by an insulin dependent 
pathway that stimulates phosphorylation of AMP-activated protein kinases (AMPK), acetyl-
CoA carbohydrate (ACC), and mitogen activated protein kinases (MAPKS); whilst, co-
treatment of saffron and insulin has been shown to improve insulin sensitivity (Kang et al., 
2012), albeit in animal or invitro models. When extended into human investigations, Saffron, 
or its constituents, has been shown to elicit positive effects on the blood lipid profile and weight 
status. For instance, Gout et al (2010) reported significant body weight reductions(Gout et al., 
2010), following a period of supplementation with a Saffron constituent, whilst, Kermani et al 
(2017) noted improvements in HDL levels and on serum pro-oxidant balance(Tayyebe 
Kermani et al., 2017), and Abedimanesh et al (2017) reported significant decreases in body 
mass index (BMI), waist circumference and fat mass values. However, compared to animal 
models, the literature is far more equivocal as to its effect in humans(Nasim Abedimanesh et 
al., 2017). Among others, Javandoost et al (2017), in a Randomized Control Trial, reported no 
significant changes in LDL, HDL or TG following supplementation(Ali Javandoost et al., 
2017); similarly, Milajerdi et al (2018) found no statistical difference in other metabolic 
parameters such as serum lipids, blood pressure, and HbA1c(Alireza Milajerdi et al., 2018). 
Notwithstanding the equivocality in human studies, no meta-analyses has been conducted to 
investigate the overall therapeutic effect of saffron, taking into consideration important aspects, 
such as dosage and supplementation period. Furthermore, given the potential of Saffron, or its 
constituents, to elicit positive reparative or preventative effects, and compliment traditional 
therapies, the aim of this study was to systematically review and meta analyses the effects of 
saffron on lipid profiles, reported in Randomized Control Trials.  
 
Methods  
Study design and Search strategy  
 
This systematic review was performed according to the PRISMA (Preferred Reporting Items 
for Systematic Reviews and Meta Analyses) statements(Moher et al., 2015). We performed a 
systematic electronic search in PubMed/MEDLINE, Cochrane and SCOPUS to identify 
randomised controlled trials (RCTs) assessing the effects of saffron on lipid profile 
(cholesterol, TG, HDL and LDL) compared with no intervention (placebo) among clinical 
population. We used the Boolean search terms (AND, OR, or NOT) in order to create the search 
strategy, merging the search terms of the exposure (saffron therapy) and the outcomes (Weight, 
cholesterol, TG, HDL and LDL). The search strategy was developed using a specific approach, 
including all the items from database inception until October 12th, 2018 and without using 
language restrictions. The details of the search strategy are reported in the Supplemental Table 
1.  
 
Selection criteria  
 
The PICOS criteria was used to select articles suitable for inclusion. All identified studies were 
obtained from each database were stored in Endnote Reference Manager X8© and duplicates 
were excluded using the Endnote function “remove duplicates”. Two authors (JR and NM) 
independently reviewed the titles, abstracts and full-texts of relevant articles to identify eligible 
studies. The criteria for study selection included the following: 1) Adult subjects (18 years and 
older); 2). RCT studies reporting mean differences (WMD) with the 95% confidence intervals 
(95% CI); 3). Studies that evaluated the effects of Saffron, Crocin, or Saffron extract on weight 
and lipid profile. The exclusion criteria included studies evaluating: 1) Treatments other than 
Saffron; 2) Outcomes other than participants weight and lipid profile; 3) Animal studies; 4) 
Studies without a placebo group or using no-randomised study designs 5) Conference abstracts, 
casereports, reviews, commentaries.  
 
Data extraction  
 
Two reviewers (JR and NM) independently extracted data from each study included in the 
review using a standardised data extraction form. Discrepancies were resolved by discussion 
with a senior author (PM). The information extracted in the form included the following: study 
authors, year of publication, geographic location, duration of follow up, sample size, mean age 
(y), saffron Dose (mg/d), and mean and standard deviation (SD) of outcome in pre- and post-
intervention. Quality assessment Studies included were assessed for their quality using the 
“Cochrane collaboration’s tool for quality assessment of randomized control trials” (Higgins 
et al., 2011), which considers the following characteristics: Selection bias (random sequence 
generation and allocation concealment), completeness of outcome data, other sources of bias, 
blinding of assessors and participants (performance bias and Outcome bias), and attrition bias. 
Each study was categorised as having a low, high or unclear risk of bias for each characteristic. 
Each study was ranked as having poor, fair or good quality according to the AHRQ Standards 
(Higgins et al., 2011). Studies were judged to be of poor quality when the random sequence 
generation, allocation concealment and blinding showed high or unclear risk of bias.  
 
Statistical analysis  
 
We assessed the effects of Saffron on lipid profile using weighted mean differences (WMD) 
with the 95% CI. When the SD of the mean difference for studies was not reported it was 
calculated by the following formula: [SD2 baseline + SD2 final – (2R x SD baseline x SD 
final)] SD2 baseline + SD2 final – (2 R* SD baseline + SD final) (Cooper, Hedges, & 
Valentine, 2009). The random-effects model (DerSimonian and Laird method) was used to 
calculate the pooled weighted mean difference (WMD). In accordance with the Cochrane 
thresholds recommendations, we used the Qtest, the I-squared and an alpha level of 0.05 for 
statistical significance to assess the heterogeneity across studies, (Green & Higgins, 2005). 
Subgroup analyses were used to identify potential causes of heterogeneity among the articles. 
The type of Saffron (Saffron, Crocin, or Saffron extract) was considered as a predefined source 
of heterogeneity. Sensitivity analysis was performed to investigate the effect of each study on 
overall analysis. We used the funnel plot and the Egger’s weighted regression tests to evaluate 
the likelihood of publication bias. The nonlinear potential effects of Saffron dosage (mg/day) 
were examined using fractional polynomial modelling. Metaregression was used to determine 
effect of duration of intervention on outcomes. All statistical tests were conducted using the 





We identified 135 published articles using our search strategy from PubMed, Scopus, and 
Cochrane Library (Supplementary Figure 1). After, removing duplicates, 96 studies were 
screened for eligibility. Seventy-two articles were excluded based on title and abstract. Ten 
other studies because of the following reasons: 1) Non-RCT design (n=5), 2) Animal trials 
(n=3), and 3) Studies that evaluated the effect of Saffron in combination with other foods and 
supplements (n=2). Fourteen articles (18 arms) representing 788 participants (N. Abedimanesh 
et al., 2017; Azimi, Ghiasvand, Feizi, Hariri, & Abbasi, 2014; Fadai et al., 2014; Gout et al., 
2010; Jafarnia et al., 2017; A. Javandoost et al., 2017; T. Kermani, T. Kazemi, et al., 2017; T. 
Kermani, M. Zebarjadi, et al., 2017; Mansoori et al., 2011; A. Milajerdi et al., 2018; 
Modaghegh, Shahabian, Esmaeili, Rajbai, & Hosseinzadeh, 2008; Mohamadpour, Ayati, 
Parizadeh, Rajbai, & Hosseinzadeh, 2013; Nikbakht-Jam et al., 2016; Sepahi et al., 2018) met 
our inclusion criteria and were included in the meta-analysis. Study characteristics 
Characteristics of eligible studies are shown in Table 1. Most studies were conducted in the 
Iran (N. Abedimanesh et al., 2017; Azimi et al., 2014; Fadai et al., 2014; Jafarnia et al., 2017; 
A. Javandoost et al., 2017; T. Kermani, T. Kazemi, et al., 2017; T. Kermani, M. Zebarjadi, et 
al., 2017; Mansoori et al., 2011; A. Milajerdi et al., 2018; Modaghegh et al., 2008; 
Mohamadpour et al., 2013; Nikbakht-Jam et al., 2016; Sepahi et al., 2018) and one in France 
(Gout et al., 2010). The sample size of the included studies ranged from 20 to 81 individuals 
with mean age of 43 years in intervention groups and 45 years in control groups. The mean 
duration of the study interventions was 7 weeks (from 1 to 12 weeks). Articles were published 
across a 10-year duration, between 2008 and 2018. The mean dose of the Saffron administered 
was 160 mg/day (5 to 1000 mg/day).  
 
Quality assessment  
 
The results of the quality assessment of included studies are provided in Table 2. Four arms 
have fair quality (Modaghegh et al., 2008; Mohamadpour et al., 2013; Nikbakht-Jam et al., 
2016), one has poor quality (Azimi et al., 2014), and thirteen have good quality (N. 
Abedimanesh et al., 2017; Fadai et al., 2014; Gout et al., 2010; Jafarnia et al., 2017; A. 
Javandoost et al., 2017; T. Kermani, T. Kazemi, et al., 2017; T. Kermani, M. Zebarjadi, et al., 
2017; Mansoori et al., 2011; A. Milajerdi et al., 2018; Sepahi et al., 2018). Most studies 
demonstrated adequate quality for key factors. Only four studies were rated as having an 
unclear risk of bias for random sequence generation or allocation concealment. 
 
 Meta-analysis results 
 
 Body Weight Six arms providing a total of 299 participants (intervention = 164, and control= 
135) reported changes in weight as an outcome measure (N. Abedimanesh et al., 2017; Azimi 
et al., 2014; Gout et al., 2010; Jafarnia et al., 2017; T. Kermani, T. Kazemi, et al., 2017). We 
combined the results using the random-effects model and showed insignificant reduction in 
weight following Saffron intervention (WMD: -0.43 kg, 95% CI: -1.33, 0.46) (Fig 1.). There 
was significant heterogeneity among studies (p=0.001). Cholesterol Sixteen studies providing 
a total of 619 participants (intervention= 353, and control= 266) reported cholesterol as an 
outcome measure (N. Abedimanesh et al., 2017; Azimi et al., 2014; Fadai et al., 2014; A. 
Javandoost et al., 2017; T. Kermani, T. Kazemi, et al., 2017; T. Kermani, M. Zebarjadi, et al., 
2017; Mansoori et al., 2011; A. Milajerdi et al., 2018; Modaghegh et al., 2008; Mohamadpour 
et al., 2013; Nikbakht-Jam et al., 2016; Sepahi et al., 2018). Pooled results from the random 
effects model showed that cholesterol levels reduced in the intervention group compared with 
the control group (WMD: -6.36 mg/dl, 95% CI: -10.58, -2.18). There was a significant 
heterogeneity among studies (p=0.001). TG Sixteen studies providing a total of 640 
participants (intervention = 353, and control = 287) reported TG as an outcome measure (N. 
Abedimanesh et al., 2017; Azimi et al., 2014; Fadai et al., 2014; A. Javandoost et al., 2017; T. 
Kermani, T. Kazemi, et al., 2017; T. Kermani, M. Zebarjadi, et al., 2017; Mansoori et al., 2011; 
A. Milajerdi et al., 2018; Modaghegh et al., 2008; Mohamadpour et al., 2013; Nikbakht-Jam et 
al., 2016; Sepahi et al., 2018). We pooled results using the random-effects model and showed 
that TG levels reduced in the Saffron group compared with the control group (WMD: -5.37 
mg/dl, 95% CI: -10.25, -0.48). There was significant heterogeneity among studies (p=0.001). 
LDL Fifteen studies providing a total of 620 participants (intervention= 343, and control= 277) 
reported LDL as an outcome measure (N. Abedimanesh et al., 2017; Azimi et al., 2014; Fadai 
et al., 2014; A. Javandoost et al., 2017; T. Kermani, T. Kazemi, et al., 2017; T. Kermani, M. 
Zebarjadi, et al., 2017; A. Milajerdi et al., 2018; Modaghegh et al., 2008; Mohamadpour et al., 
2013; Nikbakht-Jam et al., 2016; Sepahi et al., 2018). Compared with the placebo group, 
administering Saffron as intervention was not associated with a significant reduction in LDL 
levels (WMD: -3.03 mg/dl, 95% CI: -6.53, 0.47). We found significant heterogeneity among 
the studies (p= 0.001). HDL Pooled results from fifteen studies (N. Abedimanesh et al., 2017; 
Azimi et al., 2014; Fadai et al., 2014; A. Javandoost et al., 2017; T. Kermani, T. Kazemi, et al., 
2017; T. Kermani, M. Zebarjadi, et al., 2017; A. Milajerdi et al., 2018; Modaghegh et al., 2008; 
Mohamadpour et al., 2013; Nikbakht-Jam et al., 2016; Sepahi et al., 2018) using the random-
effects model indicated that Saffron as intervention resulted in non-significant increase in HDL 
levels (WMD: 0.91 mg/dl, 95% CI: -0.13, 1.96) with significant heterogeneity among the 
studies (p= 0.01).  
 
Subgroup analysis, Meta-regression, and Non-linear dose-responses  
 
The results of the subgroup analyses are summarized in Table 3. We stratified studies based on 
type of Saffron (Saffron or Crocin). This analyses showed that TG levels (WMD: -11.36 mg/dl, 
95% CI: -19.64,  3.07) decreased significantly when Saffron was used as intervention compared 
with trials that used Crocin (WMD: -0.42 mg/dl, 95% CI: -6.07, 5.21). However, the subgroup 
analyses by type of Saffron (Saffron or Crocin) did not have significant effect on change in 
weight, cholesterol, LDL, and HDL. Subgroup analysis based of the disease type of the 
participants showed this variable was not source of heterogeneity between studies. We 
performed a meta-regression analysis to examine the variation in treatment effect of Saffron 
based on duration of intervention. The meta-regression analysis suggested that duration of 
intervention was a significant sources of trial heterogeneity for HDL changes (p=0.03, 
Coef:0.5308) (Supplemental Fig 2). Although, the duration of intervention did not demonstrate 
any significant changes in cholesterol and TG levels, the results showed an indirect relation 
between them. Also, meta-regression analysis of duration of intervention showed no significant 
effect on LDL and weight. We explored the dose-response relationship between dose of Saffron 
(mg/day), TG (Pnonlinearity = 0.04, Coef=-11.1094) and cholesterol (Pnonlinearity = 0.01, 
Coef=-11.3923) (Fig 2). The TG and cholesterol reduction trend continues until 400 mg/day of 
Saffron dose and then this effect reversed. Evaluating the dose-response relationship based on 
dose of Saffron showed no significant effect on LDL and weight.  
 
Publication bias and Sensitivity analysis  
 
The Egger’s and Begg tests did not show publication bias for weight (p=0.32, p=0.34) and 
HDL (p=0.15, p=0.45) (Supplemental Fig 3). Begg tests did not show any publication bias for 
cholesterol (p=0.75), TG (p=0.72), and LDL (p=0.40) too. We identified significant publication 
bias for cholesterol (p=0.01), TG (p=0.03), and LDL (p=0.06) when using the Egger’s test ‘trim 
and fill’ method for adjusting for publication bias (Supplemental Table 2). The results of our 
sensitivity analysis did not show significant differences beyond the limits of 95% CI of 
calculated SESs for Saffron intervention studies (Supplemental Fig 4). 
 
 Discussion  
 
This systematic review and meta-analysis aimed to estimate the effect of Saffron as a health 
intervention on lipid profile. The evidence provided in this review summarizes the literature 
using high quality evidence from randomized controlled trials investigating the effects of 
Saffron on weight, cholesterol, TG, LDL, and HDL. We found evidence to suggest a reduction 
in cholesterol and TG levels when saffron was administered compared to treatment with 
placebo. The evidence from these studies was judged to be of poor quality due to inadequate 
description of randomisation or allocation concealment. Also, the clinical relevance of the 
differences demonstrated by cholesterol and TG as biomarkers among participants is unclear. 
These findings are similar to results from other published reviews supporting the therapeutic 
role of saffron on triglyceride and cholesterol (Ghaffari & Roshanravan, 2018) (20). A number 
of studies (Bathaie & Mousavi, 2010; Bukhari, Manzoor, & Dhar, 2018; Christodoulou, 
Kadoglou, Kostomitsopoulos, & Valsami, 2015; Melnyk, Wang, & Marcone, 2010) have 
reported the preventive and therapeutic benefits of Saffron through its hypotensive, hypo-
lipidemic and anti-oxidative properties. These effects are demonstrated via a number of 
pathways. Saffron decreases systolic blood pressure and mean arterial pressure (Ghaffari & 
Roshanravan, 2018) through it vaso-modulating effects and anti-inflammatory effects. It also 
exerts it therapeutic effects via its lipid-lowering effects (Shafiee et al., 2017). Other 
mechanisms of action include regulating the expression of growth factors such as adiponectin, 
tumor necrosis factor (TNF) α and leptin in adipose tissue or fat mass (Ghaffari & Roshanravan, 
2018). However, there was no evidence from this review to support the use of saffron for 
promoting weight loss and LDL compared to the placebo. Due to the nature of the evidence 
evaluating this outcomes and significant clinical differences identified between studies, clinical 
recommendations from this review is uncertain. Previous reviews evaluating the effects of 
saffron have reported evidence to support the beneficial effects for weight, HDL and LDL 
(Bukhari et al., 2018; Ghaffari & Roshanravan, 2018; Rahaiee, Moini, Hashemi, & 
Shojaosadati, 2015; Shafiee et al., 2017). However, most of the evidence from these reports 
are from animal studies and do not provide evidence of causal effects. Few of these provide 
evidence from clinical studies or supported by evidence from randomized controlled trials in 
humans with demonstrable clinical applications. The mechanism of action for the therapeutic 
effects of saffron are varied. For obesity the expression of digestive enzymes is downregulated. 
Saffron inhibits the secretion of pancreatic and gastric lipases which regulate fat absorption, 
decreasing the storage of central adipose tissue and blood circulating leptin levels. This results 
in an increased feeling of satiety (Shafiee et al., 2017). The lipid-lowering effects of Saffron 
have also been linked to the modulation of the oxidation of lipoproteins via its anti-oxidative 
properties (Ghaffari & Roshanravan, 2018). We identified sufficient number of studies that 
allowed for the evaluation of sources of heterogeneity. A sub group analysis by type of saffron 
and the disease type of the participants showed no further changes on weight, cholesterol, LDL, 
and HDL. An increased effect on TG was evident when the analysis was sub-grouped type of 
saffron (Saffron or Crocin). This finding is supported by consistent evidence from literature 
reviews suggesting greater effects when saffranal compound is used compared to 
crocin(Melnyk et al., 2010). There is a possibility that the concentration and combination of 
the components of saffron inhibit mechanistic pathways more readily than crocin. We found a 
linear dose-dependent relationship between dose of Saffron (mg/day), TG and cholesterol. We 
found no dose-response relationship for weight, HDL and LDL. But this finding may be 
masked by the size and quality of studies analyzed. Furthermore, a sub group analysis by 
duration of the intervention showed duration as a significant source of heterogeneity for HDL, 
suggesting that clinical administration for longer durations may prove beneficial. However, we 
did not observe similar changes for weight, cholesterol, LDL and TG levels. There are a number 
of limitations with this review. Although we did not identify publication bias for outcomes we 
explored, we did not explore the grey literature. The review was conducted using a specific 
search strategy, which may have limited the result of the articles found. Also, we used data 
from studies with small sample sizes, significant clinical heterogeneity and varying levels of 
the quality of the evidence, may have masked significant findings on the effect of saffron or 
variation due to systematic error. Also, the varying nature of the intervention dosage and 
durations explored in studies included in this review limited adequate clinical comparability 
and application. This limited the strength of the clinical recommendations. A maximum 
tolerated dose of 1.5g/day for saffron has been recommended as safe levels (Ghaffari & 
Roshanravan, 2018). The range for the doses of saffron administered in studies included in this 
review was 5mg/day to 1000mg/day and no major adverse events or toxic reactions were 
reported. None of the studies included in this review provided further information on the safety 
profile of saffron or crocin to aid their use as a clinical therapeutic agent(N. Abedimanesh et 
al., 2017; Azimi et al., 2014; Fadai et al., 2014; Gout et al., 2010; Jafarnia et al., 2017; A. 
Javandoost et al., 2017; T. Kermani, T. Kazemi, et al., 2017; T. Kermani, M. Zebarjadi, et al., 
2017; Mansoori et al., 2011; A. Milajerdi et al., 2018; Modaghegh et al., 2008; Mohamadpour 
et al., 2013; Nikbakht-Jam et al., 2016; Sepahi et al., 2018). the quality of the evidence 
identified limits recommendation of saffron for clinical management.  
 
Conclusion  
There is some evidence from randomised controlled trials to support the use of variants of 
saffron among patients and healthy participants. We identified some benefits on cholesterol 
and triglycerides compared to placebo. However, we suggest caution in the interpretation of 
these results due to the strength of the evidence informing this recommendation and the unclear 
clinical application. We found no difference for the use of saffron on weight, low and high 
density lipo-proteins compared to placebo. We recommend the conduct of adequately powered, 
high-quality RCTs with short and long-term follow up, evaluating relevant clinical outcomes 
to allow for making definitive recommendations. Future studies should explore the mechanistic 
pathways of saffron in humans, this is still not fully understood. Varying doses of saffron 
should be compared to confirm its efficacy using standardised methods for administering the 
extract and measuring outcomes.  
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